On January 20, 2015, the U.S. Supreme Court issued a decision in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. holding that “clear error,” not “de novo,” is the correct standard of appellate review for underlying factual...more
1/21/2015
/ Claim Construction ,
Clear Error Standard ,
De Novo Standard of Review ,
Federal Rules of Civil Procedure ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
SCOTUS ,
Teva v Sandoz
The Supreme Court’s decision in Alice Corp. Pty. Ltd. vs. CLS Bank Int’l, 134 S. Ct. 2347 (decided June 19, 2014) (“Alice”) is an important decision that will have an impact on software and computer-related inventions. In its...more
In this issue:
- Special Report: US Supreme Court Will Decide Key IP Cases in 2014
- Patent Litigation: Strategies to Battle NPEs: Lessons from the Front Lines
- Design Patents: The Federal Circuit...more